[17th May 2017, WATFORD, UK] Leading infection control specialists, GAMA Healthcare Ltd, acquires the Clinell division of their Australian distributor, AMCLA Pty Ltd., in Victoria. This significant investment demonstrates GAMA’s continued commitment to infection prevention – providing outstanding education, training and clinical support to healthcare professionals across the world.
Plans for growth, support and education
GAMA will take over the current office in Mornington, Victoria and will retain all AMCLA personnel. The business unveils ambitious investment plans to emulate success in the UK – aiming to double the current workforce over the next twelve months. With headquarters in Watford, England, GAMA now has offices in six cities, across three continents.
“This is a very exciting time for us, as we enhance our service in Australia”, says Dr Guy Braverman, Managing Director and Co-Founder of GAMA. “As world leaders in infection prevention we are committed to empowering healthcare professionals to make the right choices to achieve the best clinical outcomes. Through our growing team of experienced clinical nurse trainers and area managers, we can increase support and after-sales service to meet the individual needs of
In the UK, GAMA provides bespoke, local training through group sessions, ward-based training and practitioner meetings – delivered by a team of infection control specialists. “Our organisational support training programme is valued very highly by our UK customers and we look forward to implementing this in Australia,” says Dr Martin Kiernan, Clinical Director at GAMA. “We have developed the most advanced and fully customisable tablet-based training suite that is free to all customers. In the last six months of 2016, we hosted over 250 training days. This support has been critical in developing new business opportunities and retaining key contracts.“
Commitment to products, people and partnerships
Founded in 2004 by two medical doctors, GAMA Healthcare has become a world leading developer and manufacturer of infection prevention technology. The Clinell range is the NHS’s number 1 brand, providing a range of product lines for surface care, hygiene monitoring, and patient skincare. GAMA’s dedication to infection prevention is demonstrated through both product innovation and continued investment in people and partnerships.
For all media enquiries and interview requests please contact Beth Lowes at ROAD Communications on: firstname.lastname@example.org or call +44(0)208 995 5832.
About GAMA Healthcare
Formed in 2004 by two medical doctors, GAMA Healthcare is a world leading developer and manufacturer of infection prevention products for the healthcare sector. Their focus remains on quality, innovation and continual improvement. We work closely with our customers, identifying their needs and providing solutions to real problems. Our new and continually evolving product lines – specialising in surface care, hygiene monitoring, patient skin care and easyclean computer accessories – offer market leading solutions to infection control problems found throughout healthcare provision.
GAMA Healthcare products are marketed under the brands Clinell, Carell and Cleanall and are widely used in many hospitals in around the worldwide. In the last 13 years, they have become the largest supplier of wet and dry wipes in the United Kingdom, with at least one of their products used in every National Health Service hospital. They distribute to over 60 countries around the world and the list continues to grow.
Since 2007, AMCLA – a family owned specialist import and distribution company, have brought world class healthcare delivery solutions through their two key sales divisions: medical and pharmaceutical. AMCLA have built a reputation for supplying innovative, high quality products to healthcare markets.
Single room, anyone?
There has been lots of debate over many years about the extent to which hospitals should provide single rooms for patients. Read more…
NEW YORK (October 6, 2016) – Ultraviolet C light disinfection to clean unoccupied patient rooms significantly reduced C. difficile infections (CDI) in high-risk patients who later occupied those rooms, according to a study published today in Infection Control & Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America. The no-touch device, used after patients with CDI were discharged from the hospital, also resulted in substantial healthcare savings, estimated between $350,000 and $1.5 million annually.
“UV light disinfection is a fast, safe, and effective technology to reduce the risk of C. difficile infection associated with the hospital environment,” said David Pegues, MD, lead author of the study and a professor of Medicine in the Perelman School of Medicine at the University of Pennsylvania.
“The success of this technology is dependent on Environmental Services employees as a critical partner in our ongoing efforts to eliminate hospital-acquired infections such as C. difficile and
to improve patient safety.”
The study was conducted in three hematology-oncology units at the Hospital of the University of Pennsylvania during a one-year period (February 2014-January 2015). Results showed that adding UV disinfection to typical disinfection protocols reduced the incidence of CDI by 25 percent among new patients in these units, compared to the prior year. At the same time, CDI rates increased 16 percent in the non-study units during this period. The team found that using the ultraviolet robot after a room cleaning by members of the Environmental Services team not only reduced the number of infections, but did so without adversely impacting room turnaround time. According to this study, room cleaning took only five minutes longer on average compared to non-study units.
“These findings have real implications for both health systems and patients. The effectiveness and efficiency of UV-C robots make it a practical and cost effective technology that will benefit hospitals around the country and save people’s lives,” said Pegues.
The technique, known as ultraviolet wavelength C germicidal irradiation, uses short-wavelength ultraviolet light to kill microorganisms. CDI is one of the most common healthcare-acquired infections in the United States and is associated with serious complications. It is resistant to many surface disinfectants and can persist on surfaces, making it an ongoing risk for transmission to patients.
While the UV disinfection device proved to be effective at reducing CDI incidence, it showed no effect on other healthcare-associated infections, such as methicillin-resistant Staphylococcus aureus (MRSA).
David Pegues, Jennifer Han, Cheryl Gilmar, Brooke McDonnell, Steven Gaynes. “Impact of Ultraviolet Germicidal Irradiation for Terminal Room Disinfection on C. difficile Infection Incidence among Hematology Oncology Patients.” Web (October 6, 2016).
This year we had a great turn out for the Quiz Me game, thanks for coming along! The winners from each day were Karen Hawker, Kirsty Louise Morgan and Jean Robinson. Congratulations, enjoy your tablet and Amazon vouchers!
This years Twitter winners for the #clinellcandy stand were Carley Baker, Kerry Ord and Gary! They each had the best photo throughout the show! Congratulations, enjoy the chocolate hamper prize!